Oncimmune Holdings plc signed a framework agreement for an exclusive licence with Genostics Company Limited ('Genostics'). The agreement is for the distribution, manufacturing and future development of all products related to Oncimmune's EarlyCDT platform for the People's Republic of China, with an initial focus on EarlyCDT-Lung. Cancer is the leading cause of death in China and a major health problem and lung cancer is the number one killer of both men and women with over 700,000 cases diagnosed annually. Early diagnosis has the potential to make a significant impact as mortality increases sharply with advanced disease. The framework sets the terms for the licence agreement under which Genostics will start to sell EarlyCDT-Lung within 36 months of the date of the agreement, subject to China FDA ('CFDA') approval, although both parties expect this to be sooner. Oncimmune will receive a royalty of c.8% on the gross revenue subject to minimum royalty payments over the first six years post market entry of £15.7 million on aggregate and £5 million (index linked) per year thereafter. Oncimmune will receive a royalty of c.8% on the gross revenue subject to minimum royalty payments over the first six years post market entry of £15.7 million on aggregate and £5 million (index linked) per year thereafter.